Is Hind.Bio Science overvalued or undervalued?
As of November 3, 2024, Hind.Bio Science is considered very expensive and overvalued, with a PE ratio of 9.99 and an EV to EBITDA of 12.14, especially when compared to peers like Cipla and Dr. Reddy's Labs, despite its historical outperformance against the Sensex.
As of 3 November 2024, the valuation grade for Hind.Bio Science has moved from does not qualify to very expensive. This indicates a significant shift in perception regarding the company's valuation, suggesting that it is currently overvalued. The key ratios reveal a PE ratio of 9.99, an EV to EBITDA of 12.14, and a ROE of 30.00%. When compared to peers, Hind.Bio Science's valuation appears starkly higher than companies like Cipla, which has a PE of 22.99 and an EV to EBITDA of 15.93, and Dr. Reddy's Labs, with a PE of 19.49 and an EV to EBITDA of 12.87. The PEG ratio of 0.15 further emphasizes that the stock may not justify its current price given its growth prospects. Additionally, while the company has outperformed the Sensex over the longer term, its recent performance shows a decline of 4.02% year-to-date, contrasting with the Sensex's gain of 5.63%. Overall, Hind.Bio Science is deemed overvalued in the current market context.
{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)
{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)
Related Stock Links
- {{stockdata.stock.stock_name.value}} Analysis
- {{stockdata.stock.stock_name.value}} Technicals
- {{stockdata.stock.stock_name.value}} Quality
- {{stockdata.stock.stock_name.value}} Valuation
- {{stockdata.stock.stock_name.value}} Financial Trend
- {{stockdata.stock.stock_name.value}} Return Analysis
- {{stockdata.stock.stock_name.value}} Price Analysis
- {{stockdata.stock.stock_name.value}} Quarterly Result Analysis
- {{stockdata.stock.stock_name.value}} Half-Yearly Result Analysis
- {{stockdata.stock.stock_name.value}} Nine Monthly Result Analysis
- {{stockdata.stock.stock_name.value}} Annual Results
- {{stockdata.stock.stock_name.value}} Balance Sheet
- {{stockdata.stock.stock_name.value}} Profit & Loss
- {{stockdata.stock.stock_name.value}} Cash Flow
- {{stockdata.stock.stock_name.value}} News
- {{stockdata.stock.stock_name.value}} Announcements
- {{stockdata.stock.stock_name.value}} Share Holding
- {{stockdata.stock.stock_name.value}} Peer Comparison
Our weekly and monthly stock recommendations are here
Loading...
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Target Price
{{sm.target_price }}
({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
₹{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News
Most Read
